- Atlas
- Medicine & Health
- Translational Pharmacology
Translational Pharmacology
Translational pharmacology is the branch of pharmacology concerned with moving a drug candidate from laboratory evidence to safe, effective use in patients—and with moving clinical observations back to the laboratory to explain why drugs succeed or fail.
14 frameworks, from 1932 to today · Pharmacology · Medicine & Health
- Clinical Pharmacology and Controlled Therapeutic Trials 1932-Present
- Randomized Controlled Trial 1948-Present
- Clinical Pharmacology 1950-Present
- Pharmacogenomics 1957-Present
- Allometric Scaling 1960-Present
- Pharmacokinetics 1960-Present
- Phase I First-in-Human Trials 1960-Present
- PKPD model 1970-Present
- Biomarker and Surrogate Endpoint Strategy 1980-Present
- Proof-of-Mechanism Study Design 1990-Present
- Translational medicine 1990-Present
- Microdosing and Phase 0 Studies 2000-Present
- Model-Informed Drug Development 2000-Present
- Quantitative Systems Pharmacology 2010-Present
Overview
Translational pharmacology is the branch of pharmacology concerned with moving a drug candidate from laboratory evidence to safe, effective use in patients—and with moving clinical observations back to the laboratory to explain why drugs succeed or fail1. Its central problem is one of prediction: an experiment in cells or animals, or a trial in a small group of volunteers, must be used to forecast what will happen in a much larger, more varied population. Every method in the field is a way of making that leap less blind. The history of translational pharmacology is the history of building bridges across the "valley of death"—the gap between promising preclinical results and treatments that actually help patients2.
From Poison Trials to Controlled Comparison
For most of medical history, the question of whether a remedy worked was settled by authority and anecdote. The first systematic challenge came from controlled comparison. In the 1740s, James Lind, a naval surgeon, tested treatments for scurvy by giving different groups of sailors different remedies—including citrus fruit—and comparing outcomes. His design was imperfect by modern standards, but the principle was new: a treatment's value could be judged by comparing groups rather than by trusting tradition.
The idea matured in the twentieth century. The British Medical Research Council's 1948 trial of streptomycin in pulmonary tuberculosis, led by Austin Bradford Hill, is often cited as the first randomized controlled trial in the modern sense: patients were allocated to treatment or control by randomization, and outcomes were assessed without knowledge of allocation. This mattered because it separated the drug's effect from the natural course of disease and from the hopes of investigators. The randomized controlled trial became the gold standard for establishing efficacy, and clinical pharmacology grew around it as the discipline that studies drugs in humans—their absorption, distribution, metabolism, and excretion, and their effects at therapeutic doses.
Pharmacokinetics and the Dose–Response Problem
A drug that works in a dish may fail in a patient because it never reaches the target at sufficient concentration, or because it reaches it too long or too briefly. Pharmacokinetics—the study of how a drug moves through the body—gave translational scientists a quantitative language for this problem3. The key parameters are clearance (how fast the body eliminates the drug), volume of distribution (how widely it spreads into tissues), and half-life (how long it persists). The compartmental model, developed in the mid-twentieth century, treated the body as a set of interconnected compartments and allowed prediction of blood concentrations over time from a few measurements.
Pharmacodynamics—what the drug does to the body—was joined to pharmacokinetics in the PKPD model, which links concentration to effect4. A simple example is the Emax model, in which effect rises with concentration toward a maximum4. The PKPD framework made it possible to ask not just "does this drug work?" but "at what exposure does it work, and how does that exposure vary between patients?" This was the conceptual foundation for dose selection.
Scaling from Animals to Humans
Before any drug is given to a person, its first human dose must be chosen. The traditional approach scaled doses from animals by body weight or body surface area, assuming that a milligram per kilogram in a rat predicts a milligram per kilogram in a human. This often failed because metabolic rates scale differently across species. Allometric scaling addressed the problem by relating physiological parameters to body mass through power laws: clearance, for instance, tends to scale with body weight raised to an exponent near 0.75 rather than 1. The approach improved first-in-human dose prediction, though it remained approximate and required caution, especially for drugs with novel mechanisms.
The first-in-human trial itself became a formal milestone: a Phase I study, usually in a small number of healthy volunteers, designed to establish safety, tolerability, and pharmacokinetics rather than efficacy. The field learned hard lessons about the limits of animal prediction—most famously when a candidate drug caused severe adverse reactions in volunteers despite apparently safe animal data, underscoring that species differences in biology can be decisive.
Biomarkers and the Surrogate Endpoint
Judging a drug by whether patients live longer or feel better is slow and expensive. Translational pharmacology therefore developed biomarkers—measurable indicators of biological processes—and the surrogate endpoint, a biomarker used in place of a clinical outcome5. A well-known example is blood pressure: a drug that lowers blood pressure can be evaluated on that measure before long-term outcome trials are complete. The logic is that the surrogate lies on the causal path to the outcome. The risk is that it may not: a drug can change a surrogate without changing the disease, or even while harming patients. The field's history includes repeated cautionary cases where surrogate endpoints misled, which is why regulatory acceptance of a surrogate requires evidence linking it to clinical benefit.
Pharmacogenomics: Why Patients Differ
The observation that the same dose can cure one patient and poison another has old roots—the recognition in the 1950s that inherited differences in drug-metabolizing enzymes explained idiosyncratic reactions6. Pharmacogenomics extended this to the genome-wide study of how genetic variation affects drug response6. The practical payoff is the metabolizer phenotype: patients can be classified as poor, intermediate, extensive, or ultrarapid metabolizers of a drug, and dosing adjusted accordingly. The field moved from single-gene stories to genome-wide association studies and, in recent decades, to clinical implementation through guidelines and companion diagnostics that tie a drug's use to a genetic test. This is translational pharmacology in its purest form: a laboratory finding about a gene is converted into a dosing rule at the bedside.
Microdosing and Phase 0 Studies
A persistent translational problem is that a drug may fail in Phase I not because it is unsafe but because it never reaches its target in humans. Microdosing—giving a subtherapeutic dose, often labeled with a trace amount of radioisotope—was developed in the early 2000s as a way to measure human pharmacokinetics and target engagement before committing to full development. Phase 0 exploratory studies, conducted under relaxed regulatory requirements for small, short exposures, allow early human data on whether a candidate behaves as predicted. The approach is not universal—it cannot establish efficacy and raises questions about whether microdoses predict therapeutic doses—but it represents a distinctive translational strategy: test the hypothesis in humans as early and cheaply as possible.
Model-Informed Drug Development
By the 2000s, the pieces—pharmacokinetics, pharmacodynamics, biomarkers, pharmacogenomics, and clinical trial data—were being integrated into quantitative models used to make development decisions. Model-informed drug development (MIDD) uses mathematical models to simulate trials, predict dose–response, and support regulatory decisions, sometimes reducing the need for certain studies. The approach descends directly from the PKPD tradition and from pharmacometrics, the discipline of building mathematical models of drug behavior47. Its logic is that a well-constructed model can extract more information from limited data than any single experiment, and that decisions about dose, trial design, and patient selection can be made on quantitative grounds.
Translational Medicine as a Discipline
The term "translational medicine" crystallized in the late twentieth and early twenty-first centuries as institutions, journals, and training programs organized around the bench-to-bedside idea. The field's practitioners are not a single profession: they include clinical pharmacologists, pharmacometricians, biomarker scientists, and regulatory scientists. What unites them is the commitment to treating translation as a science in its own right—with its own methods, failure modes, and evidence standards—rather than as an automatic consequence of good laboratory work.
The Present
Today translational pharmacology is organized around a few dominant approaches. Quantitative pharmacology and MIDD are standard in regulatory submissions. Pharmacogenomic implementation is expanding, though coverage of genetic testing remains uneven. Biomarker strategy is central to trial design, with surrogate endpoints accepted for some diseases and contested for others. Microdosing and Phase 0 studies occupy a niche for selected candidates. The open questions are substantial: how to predict toxicity across species and populations, how to validate surrogate endpoints rigorously, how to make pharmacogenomic testing routine rather than exceptional, and how to shorten the interval between a promising preclinical result and a proven patient benefit. The field's history is a record of learning, often painfully, that the bridge from bench to bedside must be built deliberately—and that each new method is a further attempt to make the crossing less uncertain.
References
- Clinical pharmacology, Wikipedia
- Translational medicine (History), Wikipedia
- Pharmacokinetics, Wikipedia
- PKPD model, Wikipedia
- Biomarker, Wikipedia
- Pharmacogenomics (History, introduction), Wikipedia
- Pharmacometrics, Wikipedia
The frameworks of Translational Pharmacology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1932-Present
Clinical Pharmacology and Controlled Therapeutic Trials
How can a treatment's effect be judged fairly?
- 1948-Present
Randomized Controlled Trial
How should patients be allocated to treatments to avoid bias?
- 1950-Present
- 1957-Present
- 1960-Present
- 1960-Present
- 1960-Present
Phase I First-in-Human Trials
Is a new drug safe enough to test in people?
- 1970-Present
- 1980-Present
Biomarker and Surrogate Endpoint Strategy
Can an early measurable sign stand in for a clinical outcome?
- 1990-Present
Proof-of-Mechanism Study Design
Does the drug actually hit its intended target in humans?
- 1990-Present
Translational medicine
How can laboratory findings be turned into patient treatments?
- 2000-Present
Microdosing and Phase 0 Studies
Can tiny doses reveal human drug behavior early?
- 2000-Present
Model-Informed Drug Development
Can mathematical models guide drug development decisions?
- 2010-Present
Quantitative Systems Pharmacology
Can mechanistic models predict drug effects in disease?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Randomized Controlled Trial grew out of Clinical Pharmacology and Controlled Therapeutic Trials
The controlled therapeutic trial tradition, with its comparison of treated and untreated groups, was refined by Austin Bradford Hill into random allocation and blinded assessment in the 1948 streptomycin trial.
Carried by Austin Bradford Hill; Medical Research Council streptomycin trial (1948).
Pharmacokinetics grew out of Clinical Pharmacology
Pharmacokinetics emerged within clinical pharmacology as the quantitative study of drug absorption, distribution, metabolism and excretion, using compartmental models to predict blood concentrations.
PKPD model grew out of Pharmacokinetics
The PKPD model joined pharmacokinetics to pharmacodynamics, linking predicted concentrations to observed effects through models such as Emax.
Model-Informed Drug Development grew out of PKPD model
Model-informed drug development grew directly out of the PKPD tradition and pharmacometrics, integrating pharmacokinetic and pharmacodynamic models into quantitative decisions about dose and trial design.
Quantitative Systems Pharmacology grew out of PKPD model
Quantitative systems pharmacology extended the PKPD framework from empirical concentration-effect models to mechanistic, systems-level models of drug action in disease networks.
Clinical Pharmacology influenced by Randomized Controlled Trial
The randomized controlled trial gave clinical pharmacology its standard method for evaluating drug effects in humans, shaping how the discipline designed and interpreted studies.
Biomarker and Surrogate Endpoint Strategy influenced by Randomized Controlled Trial
The randomized controlled trial created the need for endpoints that could be measured earlier than clinical outcomes, motivating the use of biomarkers and surrogate endpoints within trial designs.
Pharmacogenomics influenced by Clinical Pharmacology
Clinical pharmacology's attention to variable drug response in patients provided the setting in which inherited differences in drug metabolism were recognized as a cause of idiosyncratic reactions.
Translational medicine influenced by Clinical Pharmacology
Clinical pharmacology supplied translational medicine with its core methods for studying drugs in humans, and clinical pharmacologists were among the discipline's founders.
Phase I First-in-Human Trials influenced by Allometric Scaling
Allometric scaling supplied the main method for choosing the first-in-human dose in Phase I trials, by extrapolating animal clearance and exposure to humans.
Phase I First-in-Human Trials influenced by Pharmacokinetics
Phase I trials took pharmacokinetic measurement as a core objective, establishing safety, tolerability and the drug's concentration-time profile in healthy volunteers.
Microdosing and Phase 0 Studies influenced by Pharmacokinetics
Microdosing used pharmacokinetic measurement, often with radiolabeled tracer doses, to test whether human exposure matched predictions before committing to therapeutic dosing.
Microdosing and Phase 0 Studies grew out of Phase I First-in-Human Trials
Microdosing and Phase 0 studies grew out of the Phase I first-in-human trial as a way to obtain early human pharmacokinetic and target-engagement data at subtherapeutic doses before full Phase I development.
Proof-of-Mechanism Study Design influenced by PKPD model
The PKPD model supplied the exposure-response reasoning used in proof-of-mechanism studies to link target engagement to downstream biological effect.
Proof-of-Mechanism Study Design influenced by Biomarker and Surrogate Endpoint Strategy
Proof-of-mechanism study design drew on biomarker strategy, using pharmacodynamic markers to demonstrate that a drug engaged its intended target in humans.
Translational medicine influenced by Biomarker and Surrogate Endpoint Strategy
Biomarker and surrogate endpoint strategy became a central method of translational medicine, providing the measurable bridge between laboratory mechanism and clinical outcome.
Model-Informed Drug Development influenced by Biomarker and Surrogate Endpoint Strategy
Biomarker and surrogate endpoint strategy supplied the endpoints and patient-selection variables that model-informed drug development simulated and optimized in trial designs.
Biomarker and Surrogate Endpoint Strategy influenced by Pharmacogenomics
Pharmacogenomics contributed genetic markers and metabolizer phenotypes that were used as biomarkers for patient selection and dose adjustment in trial design.
Model-Informed Drug Development influenced by Pharmacogenomics
Pharmacogenomic information on metabolizer status and genetic variation was incorporated into quantitative models to predict exposure and response across patient subgroups.
Beyond the field
Where Translational Pharmacology's ideas came from in other fields, and what they led to there: the strongest 12 of 80 links.
Clinical Pharmacology and Controlled Therapeutic Trials influenced by Experimental pharmacology in Pharmacology
Clinical pharmacology and controlled trials grew out of the experimental pharmacology tradition of quantifying drug action in animals and humans. The controlled clinical trial applied the experimentalist's comparison of treated and untreated groups to patients.
Clinical Pharmacology and Controlled Therapeutic Trials influenced Randomized controlled trial in Psychopharmacology
Controlled therapeutic trial methodology, crystallized in the 1948 streptomycin trial, supplied the randomization and control procedures that the psychiatric randomized controlled trial adopted.
Carried by Austin Bradford Hill.
Clinical Pharmacology grew out of Pharmacology in Pharmacy
Clinical pharmacology is the branch of pharmacology that applies drug-action knowledge to human patients. It grew directly out of the parent discipline as a clinical speciality in the mid-twentieth century.
Pharmacogenomics grew out of Classical Pharmacogenetics in Pharmacogenomics
Pharmacogenomics grew directly out of classical pharmacogenetics, extending single-gene drug-response variation to genome-wide analysis. The earlier term and findings were generalised as genomic methods arrived.
Pharmacogenomics influenced Biomarker and Precision Psychopharmacology in Psychopharmacology
Pharmacogenomics supplied the central biomarker logic of precision psychopharmacology: CYP2D6 and CYP2C19 metaboliser status and HLA variants used to predict antidepressant and antipsychotic response and adverse effects. The genotyping methods and variant-to-dose reasoning passed directly into psychiatric practice.
Pharmacokinetics influenced Physiologically based pharmacokinetic modelling in Pharmacometrics
Translational pharmacokinetics supplied the interspecies scaling and extrapolation questions that PBPK modelling was developed to answer mechanistically.
Pharmacokinetics grew out of Pharmacology in Pharmacy
Pharmacokinetics is a branch of pharmacology, applying its concepts of drug fate in the body quantitatively. It developed as a distinct quantitative subdiscipline of the parent field.
Pharmacokinetics influenced PKPD model in Pharmacometrics
PKPD modelling joins a pharmacokinetic model of concentration over time to a pharmacodynamic effect model; the PK half and its parameter-estimation methods came directly from pharmacokinetics.
Pharmacokinetics led to Clinical Pharmacokinetics in Clinical Pharmacy
Clinical pharmacokinetics is the translational application of the pharmacokinetic science filed here, carrying its concepts into bedside dose individualization from the 1970s.
PKPD model influenced by Pharmacodynamics in Clinical Pharmacology
Pharmacodynamics supplied the receptor and dose-response concepts that the PKPD model couples to concentration-time data; the integrated model is built on pharmacodynamic theory.
PKPD model influenced by Pharmacokinetics in Pharmacology
Pharmacokinetics provided the concentration-time modeling that the PKPD framework links to pharmacodynamic effect models; the PKPD model is unthinkable without pharmacokinetic theory.
Translational medicine led to Translational Bioinformatics in Health Informatics
Translational bioinformatics is the informatics branch of translational medicine, extending the bench-to-bedside programme of the 1990s to genomic and molecular data handling.

Translational Pharmacology is a planet in Nousfarer
Its city has a tower for each of these 14 frameworks. Land, walk in, and climb one concept at a time.
Land on Translational PharmacologyRelated fields
Fields its ideas are linked to
- Pharmacology 19 links
- Pharmacometrics 11 links
- Pharmacy 7 links
- Clinical Pharmacology 6 links
- Pharmacogenomics 4 links
- Pharmacokinetics 4 links
- Clinical Pharmacy 4 links
- Psychopharmacology 3 links
- Pharmacy Practice 3 links
- Medicinal Chemistry 2 links
- Health Informatics 2 links
- Comparative Effectiveness Research 2 links
More in Pharmacology
- Clinical Pharmacology
- Drug Discovery
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- Pharmacometrics
- Pharmacovigilance
- Receptor Theory And Signal Transduction
- Toxicology
See where Translational Pharmacology sits on the Map of Human Knowledge